by J. Carl Barrett* and Roger W. Wiseman* Carcinogenesis is a multistep process involving alterations in at least two distinct classes of genes. Protooncogenes are activated qualitatively or quantitatively in certain tumors, and they appear to act as positive proliferative signals for neoplastic growth. In contrast, tumor suppressor genes are normal genes that must be inactivated or lost for tumor development. When active, tumor suppressor genes control neoplastic growth in a negative manner. Chemicals may influence the carcinogenic process by mutational activation of protooncogenes and/or inactivation of tumor suppressor genes. The types of genetic alterations involved in these mutational events are diverse, and their dose-response curves may be varied. In addition, chemical carcinogens may act on nonmutational processes such as the clonal expansion of premalignant cells. The carcinogenic risk of a specific chemical is a composite of its effects on multiple genetic and epigenetic processes.
Carcinogenesis is a Multistep Process
It is generally accepted that chemical carcinogenesis is a multistep process (Fig. 1 ). Several lines of evidence supporting this conclusion are listed in Table 1 and discussed in detail elsewhere (1) . One of the underlying premises of most multistep models of carcinogenesis is that genetic and/or epigenetic alterations of multiple, independent genes are involved. While the process of chemical carcinogenesis can often be separated operationally into at least three stages, i.e., initiation, promotion, and progression (2), it is not clear how many genetic changes are involved in these operationally defined stages.
Initiation involves the induction of an irreversibly altered cell and is frequently equated with a mutational event. This conclusion is supported by the recent findings of mutational activation of ras protooncogenes in rat mammary carcinomas, mouse skin papillomas, and mouse hepatomas (3) (4) (5) (6) (7) . The mechanisms of initiation may vary, however, in different tissues or with different initiators in the same tissue (4,5). Promotion is the experimentally defined process by which the initiated cell clonally expands into a visible tumor, often a benign lesion such as a papilloma. This process undoubtedly involves epigenetic factors that selectively influence the proliferation of the initiated cell. Whether genetic mechanisms are also involved in this process is unclear. (8) . This is presumably due to its inability to elicit epidermal hyperplasia and to act a tumor promoter (8) . On the other hand, urethane is an effective hepatic carcinogen in weanling mice, presumably because cell division in the liver during development acts as an effective promoting stimulus (9) . Phorbol esters are active tumor promoters (10) , but weak complete carcinogens (11) . This is probably due to their inability to act as initiators (10 (12) . Mezerein is a weak promoter of epidermal papillomas in SENCAR mice, but it yields a similar number of carcinomas as the potent promoter TPA (13) . Likewise, the free-radical-generating chemical benzoyl peroxide is only moderately active as a tumor promoter but is far more active than TPA in inducing malignant tumors (14) . Finally, the anti-inflammatory steroid fluocinolone acetonide inhibits DMBA-initiated, 7-bromomethylbenz[a]anthracene-promoted papillomas without affecting the carcinoma incidence in treated mice (17) . These studies clearly indicate that the induction of carcinomas is only in part determined by the number and nature of the benign papillomas. Tumor promoters, although effective in producing multiple benign tumors or preneoplastic foci, are not particularly effective in influencing the progression of these lesions to malignant neoplasms in many experimental models (18, 19) . For example, in the mouse skin model, phorbol ester tumor promoters influence progression by increasing the number of precursor lesions (i.e., papillomas), but do not directly induce the transition of papillomas to carcinomas (18, 20) . Treatment of benign tumors with alkylating and other mutagenic agents increases the frequency and rate of malignant conversion (20, 21) . The promoter TPA is ineffective in enhancing malignant progression, but other promoters (e.g., benzoyl peroxide and telocidin) may effect both promotion and progression (12, 14) . These observations are important in understanding why treatment with complete carcinogens is much more effective than initiation-promotion protocols for the induction of malignant tumors (22) . Thus, the evolution of malignant tumors from benign lesions involves the acquisition of one or more qualitative changes in the precursor cells. In fact, progression probably involves multiple, heritable changes. In mouse skin, papillomas display no histopathological evidence of dysplasia after 10 weeks of tumor promotion with phorbol esters (23, 24) ; however, at later times (20-40 weeks of promotion), the papillomas show evidence of moderate to severe dysplasia and concomitantly, aneuploid tumor cells are detectable. These phenotypic changes are also observed in the carcinomas that arise from these papillomas (23) . In chemically induced rat hepatocarcinogenesis, multiple events are postulated to be involved in the progression phase (25, 26) . In other tissues, morphological evidence for multiple steps in the progression from dysplastic lesions to carcinomas in situ and ultimately to malignant carcinomas is well established (27) .
From epidemiological studies, some human carcinogens have been shown to affect predominately late stages in the carcinogenic process (28 (29, 30) , but there is little evidence for its carcinogenicity in animals (31) (32) (33) . It is inactive as an initiator or tumor promoter in a two-stage model of epidermal carcinogenesis in mice (34, 35) . Brown and Chu (36) have proposed that arsenic exposure affects a late stage in the carcinogenic process based on exposure effects in humans. These authors have further postulated that the human data are inconsistent with the hypothesis that arsenic acts during the promotion phase of the carcinogenic process. This conclusion is based on the epidemiological data that do not show reversibility of the excess lung cancer mortality after exposure ceases. Reversibility is one of the hallmarks of tumor promotion (10) . Based on these observations, we have proposed that arsenic acts specifically in the progression phase of carcinogenesis (19) . This hypothesis is supported by our recent observation that arsenic is an ef-fective inducer of gene amplification (37) and would explain why arsenic is ineffective as a complete carcinogen, initiator, or tumor promoter. Oncogene amplification has been shown in some tumors to correlate with the degree of neoplastic progression (38) (39) (40) (Table 2) . Protooncogenes are a family of cellular genes with at least 30 members that appear to be involved in normal cellular growth and development; activation or inappropriate expression of these genes results in proliferative signals involved in neoplastic growth (41, 42) . On the other hand, tumor suppressor genes are less well defined, but the function of these genes may also be to control cell division and possibly differentiation (43) (44) (45) (46) (47) (48) . For a tumor cell to emerge, these genes must be inactivated or lost (49, 50) . The number oftumor suppressor genes is unknown, but mul- tiple genes are likely to exist, possibly with limited tissue specificity (44, 48) . The mechanisms of carcinogen-induced activation of oncogenes have been elucidated, and the implications of these findings are highly important for the risk assessment of chemicals. This point can be illustrated by three examples: (a) Carcinogen-induced point mutations, resulting in activation of a ras oncogene, have been demonstrated in carcinogenesis of skin (4), mammary gland (5) , and liver (6, 7) . In these model systems, the data support the conclusion that these point mutations are the critical changes in the initiation of these tumors. These findings provide strong experimental evidence for using the linear dose-response curves observed in mutagenesis studies for carcinogen risk assessment. (b) Elucidation of oncogene activation by other genetic changes (Table 3 ) such as chromosome rearrangements and gene amplification provides a theoretical framework for the use of these end points in risk assessment. (c) The observations that normal cells are not neoplastically transformed by a single oncogene, but rather, require two or more cooperating oncogenes, support a multistep model of carcinogenesis (47, 51) and have significant implications for risk assessment of chemicals. Since at least two protooncogenes have to be activated for a tumor cell to arise and these activation events may occur by different genetic mechanisms, it is not surprising that a single carcinogen-DNA adduct or toxicological end point does not always correlate with carcinogenic potency of chemicals. Oncogenes have received a great deal of attention since their discovery, and the importance of their role in carcinogenesis has been adequately demonstrated (41, 42, 51) . However, considerable evidence exists that tumor suppressor genes play an equally important role in neoplastic development (Table 4) . Recent data from our laboratory have shown that in the multistep process of chemical carcinogen-induced neoplastic transformation of Syrian hamster embryo cells in culture, the loss of a tumor suppressor gene function is an essential step (Fig. 2) ; without the loss of this gene activity, multiple oncogenes are unable to neoplastically transform the cells (52) (53) (54) .
One important distinction between oncogenes and tumor suppressor genes is the differences in the mechanisms by which carcinogens act upon these genes (Table  2) . Protooncogenes have to be activated to influence carcinogenesis. This activation event may be a qualitative or quantitative alteration caused by point mutations, chromosome rearrangements, or gene amplification (Table 3 ). In contrast, tumor suppressor genes have to be inactivated in order for the tumorigenic phenotype to be expressed. This inactivation may result from chromosome loss, chromosome or gene deletion, recombination, gene conversion, or possibly point mutation (49, 50 
Conclusions
Chemical carcinogenesis is generally a multistep process. Not only does this process involve the stages of initiation and promotion, but also heritable alterations in multiple genes must occur during neoplastic progression. The genes involved in these multiple stages appear to represent two distinct classes: protooncogenes, which must be activated or expressed inappropriately, and tumor suppressor genes, which must be inactivated or lost. The Yamasaki is in press in Cancer Metastasis Reviews. Important insights concerning dose and time responses of complete carcinogens and promoters are discussed in this review, which is highly recommended.
